发明名称 |
TRPM-2 ANTISENSE THERAPY |
摘要 |
<p>It has now been determined that antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer. Addition of antisense TRPM-2 ODN to prostatic tumor cells in vivo is effective for delaying the onset of androgen independence. Combined use of antisense TRPM-2 and taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer. In addition, it has also been found that antisense TRPM-2 has beneficial effect for other cancer types. Specifically, antisense TRPM-2 ODN enhances chemosensitivity in human Renal cell cancer, a normally chemoresistant disease with no active chemotherapeutic agent having an objective response rate higher than 10%. Radiation sensitivity is also enhanced when cells expressing TRPM-2 are treated with antisense TRPM-2 ODN. Thus, the antisense TRPM-2 ODNs can be used to enhance hormone sensitivity, chemosensitivity and radiation sensitivity of a variety of cancer types in which expression of TRPM-2 has been observed.</p> |
申请公布号 |
EP1163254(A4) |
申请公布日期 |
2002.05.15 |
申请号 |
EP20000914710 |
申请日期 |
2000.02.25 |
申请人 |
THE UNIVERSITY OF BRITISH COLUMBIA |
发明人 |
GLEAVE, MARTIN;RENNIE, PAUL, S.;MIYAKE, HIDEAKI;NELSON, COLLEEN |
分类号 |
C12N15/09;A61K31/00;A61K31/136;A61K31/337;A61K31/66;A61K31/704;A61K31/7105;A61K38/00;A61K41/00;A61K45/06;A61K48/00;A61P5/24;A61P5/28;A61P35/00;A61P43/00;C07H21/00;C07K14/775;C12N15/113;(IPC1-7):C07H21/04;C12N15/85;C12Q1/68 |
主分类号 |
C12N15/09 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|